The risks of muscle adverse events related to use of the 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors, or statins, increase significantly with the …

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are
generally well tolerated as monotherapy. Statins are associated with two important adverse …

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are
effective in reducing the risk of coronary events, and are generally very well tolerated …

Objective To describe the most important potential adverse effects related to statin therapy,
discuss mechanisms of toxicity and drug interactions, and suggest approaches for …

Safety has become a central issue in the management of dyslipidemia with statins. A review
of New Drug Applications (NDAs) and the US Food and Drug Administration (FDA) Web site …

Objective To compare the relative hazard of muscle toxicity, renal dysfunction, and hepatic
dysfunction associated with the drug interaction between statins and concomitant …

Introduction: Lipid-lowering drugs, especially hydroxymethylglutaryl-CoA reductase
inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic …

A systematic review of cohort studies, randomized trials, voluntary notifications to national
regulatory authorities, and published case reports was undertaken to assess the incidence …

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors (statins) are
mainly considered for long-term use and often constitute part of a multiple-drug regime …

Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors
(statins), are widely used in the treatment and prevention of atherosclerotic disease. The …